Home/MapLight Therapeutics/Jonathan Gillis
JG

Jonathan Gillis

Chief Administrative and Accounting Officer

MapLight Therapeutics

MapLight Therapeutics Pipeline

DrugIndicationPhase
ML-007Schizophrenia (negative symptoms)Phase 2
ML-004Autism Spectrum Disorder (ASD)Phase 1
UndisclosedParkinson's DiseasePreclinical